Boston Scientific Corporation

(New York Stock Exchange)
Back to all articles
Slightly Bullish +15

BI Asset Management Fondsmaeglerselskab A S Has $4.49 Million Stock ...

AI-generated analysis

πŸ“‰ BI Asset Management reduced its BSX holdings by 45.1% in Q1, selling 58,923 shares while retaining a $4.49 million position.

πŸ“ˆ Other funds including Colonial Trust Co SC increased their stakes significantly, with Colonial growing its position by 502.2% to own 277 shares.

πŸ’° Insider Director Edward J. Ludwig purchased 3,580 shares at $56.68, increasing his personal holding by 16.44%.

πŸ“Š Q1 2026 revenue reached $5.20 billion, an 11.6% increase year-over-year, beating analyst estimates of $5.19 billion.

πŸ’Ή Earnings per share for the quarter were $0.80, surpassing the consensus estimate of $0.79 by $0.01.

🎯 Analyst consensus price target is set at $85.08 with an average rating of 'Moderate Buy' across major Wall Street firms.

πŸ”„ Citigroup lowered its price target to $70.00 while maintaining a 'buy' rating, indicating a more conservative valuation view.

πŸ’Έ The board approved a new $5.00 billion share repurchase program authorized on May 18th to buy back up to 6.4% of shares.

πŸ“‰ Stock price opened at $44.30, trading significantly below the 200-day simple moving average of $72.44.

πŸ₯ Boston Scientific focuses on less-invasive medical procedures for cardiovascular, digestive, and urologic conditions.

Bullish Signals
  • The company beat Q1 earnings estimates with EPS of $0.80 versus the consensus of $0.79, demonstrating operational strength.
  • Revenue grew by 11.6% year-over-year to $5.20 billion, indicating robust demand for its medical device portfolio.
  • Management has authorized a substantial $5.00 billion share repurchase program, signaling confidence in the stock's undervaluation.
  • Major institutions like Colonial Trust Co SC increased their positions significantly, with Colonial growing holdings by over 500%.
  • Insiders have been active buyers, with Directors Ludwig and Habiger purchasing shares totaling $328,734.40 in recent transactions.
  • The company maintains a strong balance sheet with a low debt-to-equity ratio of 0.42 and a healthy current ratio of 1.90.
Risk Factors
  • Wall Street Zen downgraded the stock from 'buy' to 'hold', reflecting concerns that may not be fully priced in by other analysts.
  • Several major banks including Citigroup and UBS Group lowered their price targets, suggesting potential downside risk relative to previous valuations.
  • The current trading price of $44.30 is significantly below the 200-day moving average of $72.44, indicating a prolonged downtrend or lack of recent momentum.
Full Analysis
BI Asset Management Fondsmaeglerselskab A S significantly reduced its stake in Boston Scientific Corporation (NYSE:BSX) by 45.1% during the first quarter, selling 58,923 shares to hold a remaining position of 71,593 shares valued at approximately $4.49 million. While this major institutional holder trimmed its exposure, other funds like FWL Investment Management and Swiss RE Ltd. established new positions worth roughly $26,000 each in the second and fourth quarters respectively. The stock remains heavily held by institutions at 89.07%, though insider ownership is low at 0.34%. Analyst sentiment for Boston Scientific is mixed but generally positive, with an average rating of 'Moderate Buy' and a consensus price target of $85.08. Recent reports include Citigroup lowering its target to $70.00 while maintaining a 'buy' rating, UBS Group cutting its target from $120.00 to $105.00 with a 'buy' rating, and Piper Sandler setting a $65.00 target with an 'overweight' rating. Conversely, Wall Street Zen downgraded the stock to a 'hold', reflecting varied perspectives on the company's valuation and future prospects. Financially, Boston Scientific reported strong Q1 2026 results with revenue of $5.20 billion, beating estimates by $10 million, and earnings per share of $0.80 versus a consensus of $0.79. The company grew revenue by 11.6% year-over-year and maintains healthy financial ratios including a debt-to-equity ratio of 0.42 and a P/E ratio of 18.53. Management has set Q2 2026 EPS guidance between $0.820 and $0.840, with full-year 2026 expectations ranging from $3.340 to $3.410. The company announced a new share repurchase program authorized on May 18th, allowing it to buy back up to $5.00 billion in shares, representing roughly 6.4% of its outstanding stock. This initiative signals management's confidence in the share price and commitment to returning capital to shareholders. Trading recently opened at $44.30, well below its 200-day moving average of $72.44 but above its 52-week low of $44.05, suggesting potential volatility as the stock navigates analyst target adjustments.